Bubsy 4D will launch for PlayStation 5, Xbox Series, Switch 2, PlayStation 4, Xbox One, Switch, and PC via Steam, Epic Games Store, and GOG on May 22 for $19.99, publisher Atari and developer Fabraz ...

Looking for a new fitness routine this January? Start here. Credit...Janelle Jones for The New York Times Supported by By Erik Vance Each week this January, the Well team will suggest a program of ...

Lindsey Ellefson is Lifehacker’s Features Editor. She currently covers study and productivity hacks, as well as household and digital decluttering, and oversees the freelancers on the sex and ...

Maxon has announced the Fall 2025 release of Maxon One, the company’s unified creative ecosystem that includes Cinema 4D, ZBrush, Redshift, Red Giant, and Maxon Studio. The latest Maxon One update ...

Nanoleaf this week announced the launch of the 4D V2, a product that's designed to provide ambient lighting that matches the colors on your TV set. The second version of the Screen Mirror and ...

Publisher Atari and developer Fabraz have announced Bubsy 4D for PlayStation 5, Xbox Series, Switch 2, PlayStation 4, Xbox One, Switch, and PC (Steam, Epic Games Store, GOG). A release date was not ...

Want to build the perfect starter house in Minecraft? 🏠 This easy step-by-step tutorial shows you how to create a compact, stylish, and resource-friendly house perfect for survival mode. Whether ...

In April 1982, Prof. Dan Shechtman of the Technion–Israel Institute of Technology made the discovery that would later earn him the 2011 Nobel Prize in Chemistry: the quasiperiodic crystal. According ...

Add Yahoo as a preferred source to see more of our stories on Google. An often overlooked, yet highly impactful world cinema industry in the last few decades, Chinese cinema remains widely known in ...

Please provide your email address to receive an email when new articles are posted on . Patients who received 4D-150 3E10 vg/eye experienced an 8.4 letter increase in BCVA. 4DMT is progressing to a ...

4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be pivoted toward launching late-stage studies for the biotech's eye disease ...